Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes

What Was Tested

The paper reports a study of Liraglutide in the context of fat loss, obesity & body recomposition, published as a randomized controlled trial.

GLP-1R antagonism with exendin(9-39) was used to assess GLP-1R-dependent effects during mixed meals.

Why It Was Studied

The GLP-1R antagonist exendin(9-39) and placebo were administered in a two-by-two crossover study during mixed-meal tests.

Liraglutide and diet, but not sitagliptin, caused weight loss.

How the Study Was Run

In design terms this was a randomized, placebo-controlled and crossover study.

Because people in this Liraglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The comparison arm used a placebo, so changes seen with Liraglutide could be set against what happens without it.

Each person switched between Liraglutide and the comparison at some point, usually with a gap in between.

The timeline in the abstract includes 14 weeks.

Individuals with obesity and prediabetes were randomized to receive for 14 weeks the GLP-1R agonist liraglutide, a hypocaloric diet, or the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin.

What Was Measured

The GLP-1R antagonist exendin(9-39) and placebo were administered in a two-by-two crossover study during mixed-meal tests.

PubMed files the paper under topics including Liraglutide, Insulin Resistance, Dipeptidyl Peptidase 4, Glucagon, Prediabetic State, Diet, Reducing and Obesity.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and crossover study of Liraglutide in people with fat loss, obesity & body recomposition over 14 weeks.

The publication is from 2024 (Diabetes), a journal based in United States.

More context: the Liraglutide compound page, Fat loss, obesity & body recomposition research.